Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 3:17:5727-5735.
doi: 10.2147/IJGM.S488849. eCollection 2024.

Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study

Xiang-Chong Luo #  1 , Peng Tang #  2 , Pei-Xiong Zhong  3
Affiliations

Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study

Xiang-Chong Luo et al. Int J Gen Med. .

Abstract

Objective: To explore the influence of bevacizumab combined with chemoradiotherapy on VEGF, bFGF, and Let-7 in patients with non-small cell lung cancer (NSCLC), and to analyze the factors affecting its efficacy.

Methods: Totally 150 patients with non-small cell lung cancer (NSCLC) treated in our hospital from November 2018 to November 2023 were retrospectively analyzed. The serum levels of VEGF, bFGF, and Let-7 were collected and compared. Patients were divided into good efficacy and poor efficacy groups based on short-term efficacy, and logistic regression analysis was used to analyze the factors affecting efficacy.

Results: Before treatment, there was no significant difference in the levels of VEGF, bFGF, and Let-7 between the two groups (P>0.05). After treatment, the levels of VEGF, bFGF, and Let-7 in both groups improved compared to before treatment, and compared with the control group, the study group had lower levels of VEGF and bFGF, and higher levels of Let-7, with statistically significant differences (all P<0.05). Multifactorial logistic regression analysis revealed that the course of disease, tumor diameter, and treatment regimen were independent factors influencing the therapeutic efficacy of NSCLC (all P<0.05).

Conclusion: For patients with NSCLC, the treatment regimen of bevacizumab combined with chemoradiotherapy can achieve better efficacy, with a higher objective response rate, effectively reduce the level of vascular endothelial growth factor, increase Let-7 level, and ensure safety. In addition, disease course, tumor diameter, and treatment regimen are independent factors affecting the efficacy of NSCLC. Therefore, these factors should be comprehensively considered when formulating treatment plans to ensure the best therapeutic effect.

Keywords: adverse reactions; bevacizumab; efficacy; influencing factors; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Comparison of VEGF, bFGF, and Let-7 levels in both groups. (A): Comparison of VEGF levels before and after treatment in both groups; (B): Comparison of bFGF levels before and after treatment in both groups; (C): Comparison of Let-7 levels before and after treatment in both groups.
See this image and copyright information in PMC

References

    1. Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):463–473. doi:10.1016/j.mcna.2018.12.006 - DOI - PubMed
    1. Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022;29(3):1828–1839. doi:10.3390/curroncol29030150 - DOI - PMC - PubMed
    1. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.013 - DOI - PubMed
    1. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label Phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0 - DOI - PubMed
    1. Ikeuchi N, Igata F, Kinoshita E, et al. Real-world efficacy and safety of atezolizumab plus bevacizumab, paclitaxel and carboplatin for first-line treatment of Japanese patients with metastatic non-squamous non-small cell lung cancer. Anticancer Res. 2023;43(2):713–724. doi:10.21873/anticanres.16210 - DOI - PubMed

LinkOut - more resources